

Caroline A Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10471883/publications.pdf>

Version: 2024-02-01

24
papers

4,219
citations

471061

17
h-index

610482

24
g-index

25
all docs

25
docs citations

25
times ranked

5034
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	21.5	2,886
2	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as L-Glutamine Replacements. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1213-1224.	2.9	175
3	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure-Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1607-1623.	2.9	137
4	Identification of Novel Substrates for Human Cytochrome P450 2J2. <i>Drug Metabolism and Disposition</i> , 2010, 38, 347-356.	1.7	120
5	Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. <i>Drug Metabolism and Disposition</i> , 2015, 43, 490-509.	1.7	116
6	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4572-4585.	2.9	105
7	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure-Activity Studies. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 2806-2818.	2.9	104
8	EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES. <i>Drug Metabolism and Disposition</i> , 2005, 33, 853-861.	1.7	80
9	Identifying a Selective Substrate and Inhibitor Pair for the Evaluation of CYP2J2 Activity. <i>Drug Metabolism and Disposition</i> , 2012, 40, 943-951.	1.7	78
10	P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 603-619.	1.5	64
11	Digoxin Is Not a Substrate for Organic Anion-Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but Is a Substrate for a Sodium-Dependent Transporter Expressed in HEK293 Cells. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2093-2102.	1.7	64
12	Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC50 and [I2]/IC50, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies. <i>Molecular Pharmaceutics</i> , 2010, 7, 398-411.	2.3	55
13	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	1.7	43
14	Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1367-1374.	1.7	41
15	In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1575-1583.	1.7	40
16	Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A. <i>Drug Metabolism and Disposition</i> , 2007, 35, 704-712.	1.7	37
17	Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3555-3562.	2.0	24
18	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2683-2686.	1.0	18

#	ARTICLE	IF	CITATIONS
19	Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans. <i>Drug Metabolism and Disposition</i> , 2018, 46, 532-541.	1.7	11
20	Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor. <i>Clinical Drug Investigation</i> , 2018, 38, 703-713.	1.1	7
21	Response from the International Transporter Consortium. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 75-75.	21.5	5
22	Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 657-663.	0.8	3
23	Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 647-656.	0.8	3
24	In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 108-123.	1.3	3